What are the effects of Apelix?

Apelix, as an innovative targeted therapy drug, has shown remarkable results in the treatment of advanced breast cancer. It is particularly suitable for breast cancer patients who are hormone receptor positive, human epidermal growth factor receptor2 negative and carry PIK3CA gene mutations. By precisely inhibiting the abnormal activation of the PI3K signaling pathway, Apelvis can effectively block the growth and spread of cancer cells, thereby controlling the progression of the disease.

In clinical studies, the treatment regimen of apelvis combined with fulvestrant has been proven to significantly extend the progression-free survival of patients. Compared with placebo plus fulvestrant, the median progression-free survival of the patient group using apelvis was significantly increased, which means that patients can maintain stable disease for a longer period of time and reduce the risk of disease progression. At the same time, Apelvis can also improve the overall response rate of patients, that is, make more patients' tumors shrink or disappear, thereby improving the patients' quality of life.

In addition, Apelvis also shows good synergy in combined treatment with other drugs, which can further enhance the therapeutic effect. This multi-drug combination treatment strategy provides a more comprehensive treatment for breast cancer patients and is expected to help patients obtain a better prognosis.

Apelix is not currently on the market in China, and patients who need it can only obtain it by purchasing it overseas or contacting formal overseas medical consulting companies. It is understood that Apelvis has been launched in Hong Kong. The 150 mg 56-tablet original drug produced by Swiss Novartis Pharmaceuticals costs as much as 41,000 yuan per box. In comparison, the original drug price of 150mg and 28 capsules in the Indian market is only 5,080 yuan, while the price of Lucius in Laos is as low as about 2,500 yuan. For more information about Apelis, please consult an overseas formal medical consulting company.

Overall, Apelvis has achieved remarkable results in the treatment of advanced breast cancer through its unique mechanism and mode of action, bringing new treatment options and hope to patients.